Sarcoma

Latest News

National Comprehensive Cancer Network guidelines will now include ripretinib as the ideal second-line treatment for patients with unresectable/metastatic gastrointestinal stromal tumors who are intolerant to sunitinib.
Ripretinib Receives FDA BTD for KIT+ Gastrointestinal Stromal Tumors

March 16th 2023

National Comprehensive Cancer Network guidelines will now include ripretinib as the ideal second-line treatment for patients with unresectable/metastatic gastrointestinal stromal tumors who are intolerant to sunitinib.

Results from the phase 3 DeFi trial evaluating nirogacestat in desmoid tumors demonstrate a noteworthy therapeutic advance for patients, according to an expert from Memorial Sloan Kettering Cancer Center.
Nirogacestat Yields Significant Benefit in Progressive Desmoid Tumors

March 13th 2023

Findings from a retrospective cohort study suggest that circulating tumor DNA may be an important tool for risk-stratified treatment strategies in rhabdomyosarcoma.
Baseline ctDNA May be Prognostic in Intermediate-Risk Rhabdomyosarcoma

February 25th 2023

An expert from the Smilow Cancer Hospital and Yale Cancer Center indicates that findings from the ctDNA analysis of the phase 3 INTRIGUE study were “provocative” and the subsequent phase 3 INSIGHT study has the potential to be practice changing should data be positive.
KIT Mutational Status Correlates With Response in Advanced GIST

January 25th 2023

Findings from the phase 3 INTRIGUE trial highlighted improved median progression-free survival in patients with KIT exon–mutated gastrointestinal stromal tumors who were treated with ripretinib compared with sunitinib.
Ripretinib Yields Clinical Benefit Vs Sunitinib in Pretreated GIST Harboring KIT Exon Mutations

January 9th 2023

<1
...
678910